In the study, analysis of patient samples demonstrated that high LSC17 scores meant poor outcomes with current standard treatment, even for patients who had
undergone allogeneic stem cell transplantation.
Not exact matches
Use of a lower dose of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies
undergoing allogeneic hematopoietic
stem cell transplantation (HSCT) from an unrelated donor, according to the results of a study published in Lancet Oncology.
Low - Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies: A newly published randomized phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies
undergoing allogeneic hematopoietic
stem cell transplantation from an unrelated donor.
If these results are confirmed and one or more of these FLT3 - targeted drugs become approved by the FDA, testing for the FLT3 biomarker may eliminate the need for thousands of patients to
undergo stem cell transplantation (each
allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease).